Director, GI Forecasting
Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide.
Our people are united by a shared way of working: follow the science, challenge assumptions, act with urgency and hold ourselves to a high standard of rigor—all in service of patients.
The Opportunity
Reporting to the Director, US Commercial Analytics, the Associate Director, Omnichannel Analytics will own the measurement strategy and optimization agenda for how Revolution Medicines engages healthcare professionals across channels. As RevMed scales from a single approved medicine to a multi-brand portfolio spanning pancreatic and lung cancers, customer engagement is increasingly orchestrated across field, email, media, web, and other channels, and the analytical logic connecting those channels to commercial outcomes needs a dedicated owner.&l
